Header Logo

WILLEM OVERWIJK

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
Address7455 Fannin St
Houston TX 77054-1901
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Luo W, Gardenswartz A, Hoang H, Chu Y, Tian M, Liao Y, Ayello J, Rosenblum JM, Mo X, Marcondes AM, Overwijk WW, Cripe TP, Lee DA, Cairo MS. Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma. Mol Ther Oncol. 2024 Dec 19; 32(4):200894. PMID: 39554906; PMCID: PMC11567912.
      Citations:    
    2. Rakhmilevich AL, Tsarovsky NW, Felder M, Zaborek J, Moram S, Erbe AK, Pieper AA, Spiegelman DV, Cheng EM, Witt CM, Overwijk WW, Morris ZS, Sondel PM. A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Front Immunol. 2024; 15:1419773. PMID: 39076988; PMCID: PMC11284032.
      Citations:    Fields:    Translation:AnimalsCells
    3. Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. Correction: IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2024 Feb 01; 212(3):500. PMID: 38088809.
      Citations:    Fields:    
    4. Chen R, Coleborn E, Bhavsar C, Wang Y, Alim L, Wilkinson AN, Tran MA, Irgam G, Atluri S, Wong K, Shim JJ, Adityan S, Lee JS, Overwijk WW, Steptoe R, Yang D, Wu SY. miR-146a inhibits ovarian tumor growth in?vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T?cell infiltration. Mol Ther Oncolytics. 2023 Dec 19; 31:100725. PMID: 37781339; PMCID: PMC10539880.
      Citations: 3     
    5. Hirayama AV, Chou CK, Miyazaki T, Steinmetz RN, Di HA, Fraessle SP, Gauthier J, Fiorenza S, Hawkins RM, Overwijk WW, Riddell SR, Marcondes MQ, Turtle CJ. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Adv. 2023 06 13; 7(11):2479-2493. PMID: 36332004; PMCID: PMC10242497.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    6. Primo D, Fernandez RA, Mayoral JE, Pierre-Louis L, Yao Y, Xu Y, Mu S, Miyazaki T, Prabhala R, Anderson KC, Overwijk WW, Munshi NC, Fulciniti M, Martinez-Lopez J. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19. PMID: 35882498.
      Citations:    Fields:    
    7. Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, Punt S, Williams L, Haymaker C, Chesson CB, Fa'ak F, Dominguez AL, Jones R, Kuiatse I, Caivano AR, Khounlo S, Warier ND, Marathi U, Market RV, Biediger RJ, Craft JW, Hwu P, Davies MA, Woodside DG, Vanderslice P, Diab A, Overwijk WW, Hailemichael Y. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022 07 01; 132(13). PMID: 35552271; PMCID: PMC9246385.
      Citations:    Fields:    Translation:HumansCells
    8. Singh S, Roszik J, Saini N, Singh VK, Bavisi K, Wang Z, Vien LT, Yang Z, Kundu S, Davis RE, Bover L, Diab A, Neelapu SS, Overwijk WW, Rai K, Singh M. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol. 2022; 13:794684. PMID: 35720386; PMCID: PMC9204262.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880. PMID: 34777916; PMCID: PMC8583008.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    10. Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. J Immunother Cancer. 2021 06; 9(6). PMID: 34172518; PMCID: PMC8237721.
      Citations: 6     Fields:    Translation:HumansAnimals
    11. Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975. PMID: 33722878; PMCID: PMC8023145.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    12. Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A, Milton DR. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021 08; 11(8):1996-2013. PMID: 33707233; PMCID: PMC8544022.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    13. Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Madakamutil L, Overwijk WW, Zalevsky J, Gordon N, Kivim?e S. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937. PMID: 33152115; PMCID: PMC7984260.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    14. Overwijk WW, Tagliaferri MA, Zalevsky J. Engineering IL-2 to Give New Life to T Cell Immunotherapy. Annu Rev Med. 2021 01 27; 72:281-311. PMID: 33158368.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    15. Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu P, Dominguez AL, Forget MA. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother. 2021 Apr; 70(4):1101-1113. PMID: 33123754; PMCID: PMC7979613.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    16. Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW, Forget MA. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661. PMID: 32005826; PMCID: PMC6994577.
      Citations: 40     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    17. Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620. PMID: 30647079; PMCID: PMC6467811.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    18. Zhao J, Xiao Z, Li T, Chen H, Yuan Y, Wang YA, Hsiao CH, Chow DS, Overwijk WW, Li C. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano. 2018 10 23; 12(10):9881-9893. PMID: 30231203; PMCID: PMC6245606.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    19. Hailemichael Y, Singh M, Overwijk W. Vaccinating with Stem Cells to Stop Cancer. Trends Mol Med. 2018 06; 24(6):524-526. PMID: 29731352.
      Citations: 1     Fields:    Translation:AnimalsCells
    20. Khong H, Volmari A, Sharma M, Dai Z, Imo CS, Hailemichael Y, Singh M, Moore DT, Xiao Z, Huang XF, Horvath TD, Hawke DH, Overwijk WW. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol. 2018 05 15; 200(10):3464-3474. PMID: 29643190; PMCID: PMC5940548.
      Citations: 8     Fields:    Translation:AnimalsCellsPHPublic Health
    21. Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354. PMID: 29480817; PMCID: PMC5873868.
      Citations: 37     Fields:    Translation:AnimalsCells
    22. Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018 03; 159:215-228. PMID: 29331808; PMCID: PMC6203960.
      Citations: 26     Fields:    Translation:AnimalsCells
    23. Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M, Garbe C. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 11 16; 15(1):236. PMID: 29145885; PMCID: PMC5691855.
      Citations: 11     Fields:    Translation:HumansCells
    24. Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447. PMID: 29129918; PMCID: PMC5682289.
      Citations: 37     Fields:    Translation:AnimalsCells
    25. Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017 10 17; 5(1):79. PMID: 29037250; PMCID: PMC5644253.
      Citations: 88     Fields:    Translation:Humans
    26. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350; PMCID: PMC5690831.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    27. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548; PMCID: PMC5722500.
      Citations: 24     Fields:    
    28. Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26. PMID: 29872708; PMCID: PMC5871917.
      Citations: 40     
    29. Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017 Aug; 47:103-109. PMID: 28806603.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    30. Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. Absence of Grail promotes CD8+ T cell anti-tumour activity. Nat Commun. 2017 08 10; 8(1):239. PMID: 28798332; PMCID: PMC5552797.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    31. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057. PMID: 28371827; PMCID: PMC5570198.
      Citations: 165     Fields:    Translation:HumansCells
    32. Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164. PMID: 28754817; PMCID: PMC5748156.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    33. Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017 Aug; 27(8):1034-1045. PMID: 28685773; PMCID: PMC5539354.
      Citations: 111     Fields:    Translation:HumansAnimalsCells
    34. Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249. PMID: 28254151; PMCID: PMC6197604.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    35. Overwijk WW. The making of a killer (T cell). Oncotarget. 2017 Feb 14; 8(7):10767-10768. PMID: 28199955; PMCID: PMC5355215.
      Citations:    Fields:    
    36. Zhou D, DeLyria ES, Wen X, Lu W, Thapa P, Liu C, Li D, Bassett RL, Overwijk WW, Hwu P, Li C, Ma Q. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. J Immunother. 2017 01; 40(1):11-20. PMID: 27681378; PMCID: PMC5138115.
      Citations: 6     Fields:    Translation:HumansAnimals
    37. Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD. Temporally Programmed CD8a+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep. 2016 12 06; 17(10):2503-2511. PMID: 27926855; PMCID: PMC5204262.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    38. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850. PMID: 27821490; PMCID: PMC5875182.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    39. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 2016 11; 4(11):983-994. PMID: 27697858.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    40. Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016; 4:56. PMID: 27660710; PMCID: PMC5028954.
      Citations: 47     Fields:    
    41. Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM, Galon J. Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. J Immunother Cancer. 2016; 4:37. PMID: 27330810; PMCID: PMC4915147.
      Citations:    Fields:    
    42. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722; PMCID: PMC5082984.
      Citations: 385     Fields:    Translation:HumansCells
    43. Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48. PMID: 26658052; PMCID: PMC4827047.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    44. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P, Liz?e G. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16. PMID: 26645196; PMCID: PMC4744499.
      Citations: 581     Fields:    Translation:HumansAnimalsCells
    45. Singh M, Overwijk WW. Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother. 2015 Jul; 64(7):911-21. PMID: 26050024; PMCID: PMC11028428.
      Citations: 13     Fields:    Translation:HumansCells
    46. Anthony SM, Howard ME, Hailemichael Y, Overwijk WW, Schluns KS. Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS One. 2015; 10(3):e0120274. PMID: 25756182; PMCID: PMC4354909.
      Citations: 15     Fields:    Translation:AnimalsCells
    47. Smyth MJ, Drake CG, Abastado JP, Apte RN, Blay JY, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Gabrilovich DI, Gilboa E, Gnjatic S, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, van der Burg SH, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC, Apetoh L, Ayyoub M, Bonneville M, Comin-Anduix B, Fridman WH, J?ger D, Tartour E, Valmori D, van der Bruggen P, van den Eynde BJ. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. PMID: 26137416; PMCID: PMC4485711.
      Citations: 70     Fields:    
    48. Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol. 2015 Feb 02; 108:20.1.1-20.1.43. PMID: 25640991; PMCID: PMC4361407.
      Citations: 11     Fields:    Translation:AnimalsCellsPHPublic Health
    49. Overwijk WW. Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells. Nat Med. 2015 Jan; 21(1):12-4. PMID: 25569544; PMCID: PMC6055476.
      Citations: 3     Fields:    Translation:HumansCells
    50. Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. 2016 07 03; 35(4):325-339. PMID: 25259408; PMCID: PMC5257246.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    51. Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31. PMID: 25252955; PMCID: PMC4201984.
      Citations: 63     Fields:    Translation:AnimalsCells
    52. Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014 Aug; 7(4):484-92. PMID: 24969538; PMCID: PMC4202801.
      Citations: 20     
    53. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014 Jun; 20(6):676-81. PMID: 24859530; PMCID: PMC4048321.
      Citations: 92     Fields:    Translation:AnimalsCells
    54. Hailemichael Y, Overwijk WW. Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int J Biochem Cell Biol. 2014 Aug; 53:46-50. PMID: 24796845; PMCID: PMC4111967.
      Citations: 10     Fields:    Translation:HumansCells
    55. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459. PMID: 24619206; PMCID: PMC4112501.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    56. Overwijk WW, Wang E, Marincola FM, Restifo NP, Rammensee HG. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer. 2013; 1:11. PMID: 24829748; PMCID: PMC4019909.
      Citations: 32     Fields:    
    57. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86. PMID: 23603862; PMCID: PMC3799876.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    58. Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology. 2013 Jul 01; 2(7):e24743. PMID: 24073366; PMCID: PMC3782014.
      Citations: 13     Fields:    
    59. Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P, Prieto VG. Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype. Am J Dermatopathol. 2013 Apr; 35(2):184-90. PMID: 23147350.
      Citations: 13     Fields:    Translation:Humans
    60. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72. PMID: 23455713; PMCID: PMC3618499.
      Citations: 214     Fields:    Translation:AnimalsCells
    61. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA, Liz?e G. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31. PMID: 23307859; PMCID: PMC3752683.
      Citations: 404     Fields:    Translation:HumansCells
    62. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Hwu P, Liz?e G. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403. PMID: 23204132; PMCID: PMC4120472.
      Citations: 167     Fields:    Translation:HumansAnimalsCells
    63. Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P, Liz?e G. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90. PMID: 23092383.
      Citations: 65     Fields:    Translation:Humans
    64. Yang Y, Liu C, Peng W, Overwijk WW, Liu Y, Woodman SE, Hwu P, Liz?e G. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43. PMID: 22936666; PMCID: PMC3512233.
      Citations: 30     Fields:    Translation:AnimalsCells
    65. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Radvanyi L, Hwu P, Liz?e G. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18. PMID: 22915761; PMCID: PMC3476734.
      Citations: 185     Fields:    Translation:AnimalsCells
    66. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012 Jun 01; 188(11):5365-76. PMID: 22529296; PMCID: PMC3358566.
      Citations: 65     Fields:    Translation:AnimalsCells
    67. Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Zhou D, Overwijk WW, Hwu P, Liz?e G. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82. PMID: 22421945; PMCID: PMC3860320.
      Citations: 20     Fields:    Translation:AnimalsCells
    68. Sikora AG, Hailemichael Y, Overwijk WW. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy. 2012 Feb; 4(2):141-3. PMID: 22339456.
      Citations:    Fields:    Translation:HumansCells
    69. Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, Rodr?guez-Cruz TG, Liz?e G. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011; 6(8):e22939. PMID: 21860662; PMCID: PMC3157908.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    70. Li HS, Gelbard A, Martinez GJ, Esashi E, Zhang H, Nguyen-Jackson H, Liu YJ, Overwijk WW, Watowich SS. Cell-intrinsic role for IFN-a-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood. 2011 Oct 06; 118(14):3879-89. PMID: 21828128; PMCID: PMC3193265.
      Citations: 31     Fields:    Translation:AnimalsCells
    71. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91. PMID: 21632855; PMCID: PMC3139726.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    72. Lou Y, Liu C, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P, Liz?e G. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88. PMID: 21389870; PMCID: PMC6119202.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    73. Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine ?-defensin2 fusion protein vaccines. Vaccine. 2011 Apr 18; 29(18):3476-82. PMID: 21382485.
      Citations: 9     Fields:    Translation:AnimalsCells
    74. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Hwu P, Liz?e G. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68. PMID: 20889916; PMCID: PMC3476703.
      Citations: 103     Fields:    Translation:AnimalsCells
    75. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61. PMID: 20388845; PMCID: PMC2936966.
      Citations: 23     Fields:    Translation:AnimalsCells
    76. Frasca L, Stonier SW, Overwijk WW, Schluns KS. Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. J Leukoc Biol. 2010 Jul; 88(1):69-78. PMID: 20354106; PMCID: PMC2892527.
      Citations: 7     Fields:    Translation:AnimalsCells
    77. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44. PMID: 20215556; PMCID: PMC2858983.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    78. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov 20; 31(5):787-98. PMID: 19879162; PMCID: PMC2787786.
      Citations: 322     Fields:    Translation:AnimalsCells
    79. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009 Jun 15; 182(12):7398-407. PMID: 19494262; PMCID: PMC2774140.
      Citations: 58     Fields:    Translation:AnimalsCells
    80. Overwijk WW, Schluns KS. Functions of ?C cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol. 2009 Aug; 132(2):153-65. PMID: 19428306; PMCID: PMC2761713.
      Citations: 39     Fields:    Translation:AnimalsCells
    81. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8. PMID: 19200815; PMCID: PMC5772602.
      Citations: 29     Fields:    Translation:AnimalsCells
    82. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14342-6. PMID: 18794521; PMCID: PMC2567214.
      Citations: 106     Fields:    Translation:AnimalsCells
    83. Liu C, Lou Y, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P, Liz?e G. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75. PMID: 18259609; PMCID: PMC2230660.
      Citations: 129     Fields:    Translation:AnimalsCells
    84. Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6. PMID: 18157006; PMCID: PMC2235937.
      Citations: 33     Fields:    Translation:AnimalsCells
    85. Liu S, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P, Liz?e G. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21. PMID: 17898044.
      Citations: 33     Fields:    Translation:AnimalsCells
    86. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61. PMID: 17933439.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    87. Radvanyi LG, Overwijk WW, Hwu P, Liz?e G. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006 Aug 15; 12(16):4794-803. PMID: 16914564.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    88. Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006 May 01; 176(9):5213-22. PMID: 16621986; PMCID: PMC2242845.
      Citations: 34     Fields:    Translation:AnimalsCells
    89. Radvanyi LG, Overwijk WW, Hwu P, Liz?e G. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2359s-2365s. PMID: 16609059.
      Citations: 11     Fields:    Translation:HumansAnimals
    90. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol. 2005 Apr; 17(2):187-94. PMID: 15766680.
      Citations: 21     Fields:    Translation:HumansCells
    91. Antony PA, Piccirillo CA, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP, Akpinarli A. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005 Mar 01; 174(5):2591-601. PMID: 15728465; PMCID: PMC1403291.
      Citations: 312     Fields:    Translation:AnimalsCells
    92. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80. PMID: 12925674; PMCID: PMC2194177.
      Citations: 496     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    93. Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate. 2002 Nov 01; 53(3):183-91. PMID: 12386918; PMCID: PMC2042541.
      Citations: 3     Fields:    Translation:AnimalsCells
    94. Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 2001 Nov 01; 61(21):7920-4. PMID: 11691813; PMCID: PMC2247477.
      Citations: 42     Fields:    Translation:AnimalsCells
    95. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001 Aug 20; 194(4):481-9. PMID: 11514604; PMCID: PMC2193490.
      Citations: 79     Fields:    Translation:AnimalsCells
    96. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.1. PMID: 18432774; PMCID: PMC2763508.
      Citations: 170     Fields:    Translation:HumansAnimalsCells
    97. Zoeteweij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, Yarchoan R, Orenstein JM, Blauvelt A. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. Blood. 2001 Apr 15; 97(8):2374-80. PMID: 11290600.
      Citations: 27     Fields:    Translation:HumansCells
    98. Overwijk WW, Restifo NP. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol. 2001 Jan; 22(1):5-7. PMID: 11286676; PMCID: PMC1679661.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    99. Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res. 2000 Jun; 20(6):589-96. PMID: 10888115; PMCID: PMC2078235.
      Citations: 7     Fields:    Translation:AnimalsCellsPHPublic Health
    100. Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A. 2000 May 09; 97(10):5492-7. PMID: 10779556; PMCID: PMC25856.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    101. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000 Apr 03; 191(7):1221-32. PMID: 10748239; PMCID: PMC2193167.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    102. Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S76-80. PMID: 10685664; PMCID: PMC2538796.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    103. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000 Jan 15; 164(2):562-5. PMID: 10623795; PMCID: PMC2239008.
      Citations: 47     Fields:    Translation:AnimalsCells
    104. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000 Jan 15; 60(2):253-8. PMID: 10667570; PMCID: PMC2238820.
      Citations: 25     Fields:    Translation:AnimalsCells
    105. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2000; 20(6):433-50. PMID: 11396680; PMCID: PMC2543120.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    106. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2982-7. PMID: 10077623; PMCID: PMC15881.
      Citations: 95     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    107. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Imperiale MJ, Restifo NP, Sanda MG, Mul? JJ. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst. 1999 Jan 20; 91(2):169-75. PMID: 9923859; PMCID: PMC2249695.
      Citations: 8     Fields:    Translation:HumansCells
    108. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst. 1998 Dec 16; 90(24):1881-7. PMID: 9862625; PMCID: PMC2249692.
      Citations: 9     Fields:    Translation:AnimalsCells
    109. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998 Nov 15; 161(10):5313-20. PMID: 9820504; PMCID: PMC2239007.
      Citations: 115     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    110. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998 Jul 20; 188(2):277-86. PMID: 9670040; PMCID: PMC2212458.
      Citations: 224     Fields:    Translation:HumansAnimalsCells
    111. Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother. 1997 Jul; 20(4):276-86. PMID: 9220317; PMCID: PMC2562268.
      Citations: 7     Fields:    Translation:HumansCells
    112. Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997 Jun; 12(2):117-23. PMID: 9184376.
      Citations: 26     Fields:    Translation:AnimalsCells
    113. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3183-8. PMID: 9096367; PMCID: PMC20343.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    114. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 1997 Mar; 15(4):387-94. PMID: 9141209; PMCID: PMC1950787.
      Citations: 31     Fields:    Translation:AnimalsCells
    115. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997 Jan; 20(1):15-25. PMID: 9101410; PMCID: PMC2538953.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    116. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol. 1996; 397:7-13. PMID: 8718576; PMCID: PMC2562214.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    117. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant. International Reviews of Immunology.
    118. Soluble interleukin-15 complexes are generated in vivo by type i interferon dependent and independent pathways. PLoS One. 10.
    119. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    120. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. Journal of Immunotherapy.
    121. Adjuvants for peptide-based cancer vaccines. Journal for ImmunoTherapy of Cancer. 4.
    122. Tumor immunology and cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 3.
    123. Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. Journal for ImmunoTherapy of Cancer. 4.
    124. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7:484-492.
    125. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology. 18:639-648.
    126. Mining the mutanome. Journal for ImmunoTherapy of Cancer. 1.
    127. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 97:12932.
    128. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy with Increased Retention in Tumor and Draining Lymph Nodes after Intratumoral Injection in a Mouse Model of Melanoma. Journal of Immunotherapy. 40:11-20.
    129. Peptide-based anticancer vaccines the making and unmaking of a T-cell graveyard. OncoImmunology. 2.
    130. Cancer Discovery. 6:202-216.
    131. Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Reports. 17:2503-2511.
    132. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (United States).
    133. Mouse model for pre-clinical study of human cancer immunotherapy. Current protocols in immunology / edited by John E. Coligan ... [et al.]. 2015:20.1.1-20.1.43.
    134. Consensus nomenclature for CD8+ T cell phenotypes in cancer. OncoImmunology. 4.
    OVERWIJK's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (472)
    Explore
    _
    Co-Authors (109)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _